GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
49.51
+0.83 (1.71%)
At close: Oct 30, 2026, 4:00 PM EDT
49.60
+0.09 (0.18%)
After-hours: Oct 30, 2026, 7:49 PM EDT
GSK Revenue
GSK had revenue of 8.89B GBP in the quarter ending September 30, 2026, with 3.98% growth. This brings the company's total for the last twelve months to 33.54B, up 4.28% year-over-year. In the year 2025, GSK had annual revenue of 32.67B with 4.11% growth.
Revenue (ttm)
33.54B GBP
Revenue Growth
+4.28%
P/S Ratio
2.24
Revenue / Employee
501,833 GBP
Employees
66,841
Market Cap
99.63B USD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full GSK breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.67B | 1.29B | 4.11% |
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | -9.40B | -27.58% |
| Dec 31, 2020 | 34.10B | 345.00M | 1.02% |
| Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
| Dec 31, 2018 | 30.82B | 635.00M | 2.10% |
| Dec 31, 2017 | 30.19B | 2.30B | 8.24% |
| Dec 31, 2016 | 27.89B | 3.97B | 16.58% |
| Dec 31, 2015 | 23.92B | 917.00M | 3.99% |
| Dec 31, 2014 | 23.01B | -3.50B | -13.20% |
| Dec 31, 2013 | 26.51B | 74.00M | 0.28% |
| Dec 31, 2012 | 26.43B | -956.00M | -3.49% |
| Dec 31, 2011 | 27.39B | -1.01B | -3.54% |
| Dec 31, 2010 | 28.39B | 24.00M | 0.08% |
| Dec 31, 2009 | 28.37B | 4.02B | 16.49% |
| Dec 31, 2008 | 24.35B | 1.64B | 7.20% |
| Dec 31, 2007 | 22.72B | -509.00M | -2.19% |
| Dec 31, 2006 | 23.23B | 1.57B | 7.23% |
| Dec 31, 2005 | 21.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 67.38B |
| AbbVie | 66.01B |
| Pfizer | 63.70B |
| AstraZeneca | 62.38B |
| Novartis AG | 57.36B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
| Bristol-Myers Squibb Company | 50.03B |
GSK News
- 3 days ago - GSK price target lowered to 1,925 GBp from 1,975 GBp at RBC Capital - TheFly
- 3 days ago - Jefferies downgrades GSK on reduced earnings momentum - TheFly
- 3 days ago - Glaxo shares slump amid concerns over its vaccine pipeline of new drugs as patent losses loom - This is Money
- 3 days ago - GSK (GSK) Q3 2026 Earnings Call Transcript - The Motley Fool
- 4 days ago - What GSK (GSK) Said on Its Q3 Earnings Call - MarketBeat
- 4 days ago - What GSK (GSK) Said on Its Q3 Earnings Call - Nasdaq
- 4 days ago - GSK Tumbles As Vaccine Sales Dip, Dragging On Topline Beat - Investor's Business Daily
- 4 days ago - GSK shares dive as weaker sales and mounting costs unnerve investors - The Guardian